Primary Open-angle Glaucoma Clinical Trial
— POAGOfficial title:
Modified Trabeculectomy With an Extended Subscleral Tunnel Versus Conventional Trabeculectomy for Management of Primary Open Angle Glaucoma (POAG)
NCT number | NCT03480711 |
Other study ID # | N-38-2018 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | July 10, 2018 |
Est. completion date | March 2, 2019 |
Verified date | July 2022 |
Source | Cairo University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
- To evaluate prospectively the surgical outcome in terms of intraocular pressure control, potential advantages, disadvantages, success rate, complications and bleb morphology of this modified trabeculectomy with an extended subscleral tunnel (ESST) in comparison to the conventional subscleral trabeculectomy (SST) in management of uncontrolled primary open angle glaucoma. - This study will recruit 40 eyes of (40) candidate patients with primary open angle glaucoma (POAG) who are indicated for surgery. - The candidate patients will be recruited into 2 equal comparative groups. In group (A) 20 eyes (20 patients) who will undergo conventional (SST) with intraoperative mitomycin C (MMC) (0.03%) and group (B); 20 eyes of 20 patients will undergo trabeculectomy with an ESST also with intraoperative adjunctive MMC (0.03%).
Status | Completed |
Enrollment | 40 |
Est. completion date | March 2, 2019 |
Est. primary completion date | February 28, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 40 Years to 70 Years |
Eligibility | Inclusion Criteria: - Patients with POAG aged from (40- 70) years who are candidate for glaucoma surgery with BCVA = 3/60 to be able to perform visual field testing. - Non- compliant patients to the medical treatment willing for follow-up visits for at least 6 months post-operatively . Exclusion Criteria: - Congenital, traumatic, neovascular, uveitic glaucomas or cases with angle closure glaucoma (ACG) associated with shallow AC. - Undergoing simultaneous cataract surgery. - Previous vitreo-retinal surgery including vitrectomy and buckling surgery. - Other pre-existing ocular cicatrizing diseases. - Corneal abnormality that precluded reliable applanation tonometry. |
Country | Name | City | State |
---|---|---|---|
Egypt | Faculty of medicind | Cairo |
Lead Sponsor | Collaborator |
---|---|
Rehab mahmoud abdelhamid mohamed | Cairo University |
Egypt,
El Sayyad F, Belmekki M, Helal M, Khalil M, El-Hamzawey H, Hisham M. Simultaneous subconjunctival and subscleral mitomycin-C application in trabeculectomy. Ophthalmology. 2000 Feb;107(2):298-301; discussion 302. — View Citation
Nuijts RM, Vernimmen RC, Webers CA. Mitomycin C primary trabeculectomy in primary glaucoma of white patients. J Glaucoma. 1997 Oct;6(5):293-7. Review. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | change from baseline intraocular pressure at first day postoperative | mmHg | day one postoperatively | |
Primary | change from baseline intraocular pressure at 4 weeks | mmHg | , 4 weeks. | |
Primary | change from baseline intraocular pressure at 6 weeks Ultrasound bimicroscopy (UBM) | mm Hg | 6 weeks post-operatively. | |
Primary | change from baseline intraocular pressure at 3 months | mmHg | 3 months postoperatively | |
Primary | change from baseline intraocular pressure at 6 months | mmHg | 6 months postoperatively | |
Secondary | change from baseline best corrected visual acuity (BCVA) at 6 months | logarithm of minimal angle of resolution (log MAR) | at the end of 6 months | |
Secondary | extent of filtering bleb area by ultrasound of bio-microscopy (UBM) | width, depth and height of filtering bleb area in millimeter | 6 weeks postoperatively |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01841437 -
Glaukos® iStent® Trabecular Micro-Bypass Stent System In Conjunction With Cataract Surgery Postmarket Registry
|
N/A | |
Completed |
NCT02077231 -
Study of Vitamin A and Carbomer in Comforting the Ocular Surface Irritations of Glaucoma Patients
|
N/A | |
Completed |
NCT01410188 -
Safety/Efficacy Study: OPA-6566 Ophthalmic Solution in Subjects With Primary Open-Angle Glaucoma or Ocular Hypertension
|
Phase 1/Phase 2 | |
Recruiting |
NCT05557058 -
GORE Glaucoma Drainage Implant Clinical Study
|
N/A | |
Not yet recruiting |
NCT03924544 -
Decorin in Sub Scleral Trabeculectomy
|
Phase 1 | |
Active, not recruiting |
NCT03673644 -
Impact of Glaucoma and Visual Field Loss on Life Space
|
||
Completed |
NCT03365778 -
Educational Intervention to Adopt SLT as First-Line Glaucoma Treatment
|
N/A | |
Completed |
NCT01915940 -
Bimatoprost Ocular Insert Compared to Topical Timolol Solution in Patients With Glaucoma or Ocular Hypertension
|
Phase 2 | |
Completed |
NCT03889652 -
Optical Coherence Tomography of Nerve Fiber Layer and Ganglion Cell Complex After Cataract Extraction
|
||
Terminated |
NCT03273907 -
Post Approval Study of the CyPass System
|
N/A | |
Recruiting |
NCT03193333 -
PRO-122 Versus Concomitant Therapy in Subjects With Uncontrolled Primary Open-angle Glaucoma (PRO-122LATAM)
|
Phase 3 | |
Recruiting |
NCT03921931 -
Retinal Photoreceptor Outer Segment Length Before and After Light Stimulation - a Pilot Study
|
N/A | |
Not yet recruiting |
NCT04609345 -
Prevalence of Ocular Surface Disease in Malaysian Glaucoma Patients
|
||
Recruiting |
NCT05264818 -
Assessment of Endothelial Glycocalyx in Patients With Primary Open-angle Glaucoma
|
||
Completed |
NCT04333433 -
PRESERFLO® MicroShunt Extension Study
|
||
Enrolling by invitation |
NCT02144103 -
Effectiveness and Safety of Adipose-Derived Regenerative Cells for Treatment of Glaucomatous Neurodegeneration
|
Phase 1/Phase 2 | |
Completed |
NCT01281020 -
Adherence With Fixed Versus Unfixed Glaucoma Therapy
|
||
Recruiting |
NCT04891588 -
Switching From the Preserved to the Preservative - Free Latanoprost - Timolol FC in Glaucoma Patients With OSD
|
N/A | |
Completed |
NCT03145129 -
PAIR Study-PAP And IOP Relationship: Study 2
|
||
Completed |
NCT03104621 -
Efficacy and Tolerability of Preservative-free 0.0015% Tafluprost in Glaucoma Patients
|
Phase 4 |